UiPath (NYSE:PATH) Trading Down 0.9%

UiPath Inc. (NYSE:PATH)’s share price traded down 0.9% during mid-day trading on Monday . The stock traded as low as $18.49 and last traded at $18.58. 1,486,359 shares changed hands during trading, a decline of 83% from the average session volume of 8,816,817 shares. The stock had previously closed at $18.75.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Evercore ISI raised their price objective on shares of UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a research report on Thursday, March 14th. TD Cowen raised their price objective on shares of UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, March 14th. BMO Capital Markets raised their price objective on shares of UiPath from $24.00 to $28.00 and gave the stock a “market perform” rating in a research report on Thursday, March 14th. DA Davidson raised their price objective on shares of UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, March 14th. Finally, Mizuho increased their target price on shares of UiPath from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.41.

UiPath Stock Up 3.4 %

The company’s fifty day moving average is $22.55 and its two-hundred day moving average is $21.56. The stock has a market cap of $11.12 billion, a price-to-earnings ratio of -114.93 and a beta of 0.96.

UiPath (NYSE:PATH) last issued its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. The firm had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. Sell-side analysts predict that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the sale, the chief financial officer now owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 72,000 shares of company stock valued at $1,591,360. 31.03% of the stock is owned by corporate insiders.

Institutional Trading of UiPath

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC grew its position in UiPath by 3.1% in the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after buying an additional 426 shares during the last quarter. 180 Wealth Advisors LLC boosted its position in shares of UiPath by 0.3% during the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after purchasing an additional 492 shares in the last quarter. Bleakley Financial Group LLC boosted its position in shares of UiPath by 4.9% during the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after purchasing an additional 598 shares in the last quarter. Simplicity Solutions LLC boosted its position in shares of UiPath by 4.9% during the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after purchasing an additional 598 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of UiPath by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after purchasing an additional 632 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.